Micar21.com is a drug discovery factory
  • PIPELINE
  • COMPANY
    • About us
    • Team
      • management team filip fratev
      • management team dimitar dimitrov
      • management team elina mihaylova
      • management team miguel rivera
    • Partners
    • Business model
    • Careers
    • Contact us
  • NEWS & PUBLICATIONS
    • Company news
      • Micar 21 Ltd started to provide to customers discovery of novel active substances for medicinal cosmetics development.
      • New! A pioneering study focused on the prevention of hypertrophic cardiomyopathy (HCM) among individuals with a sarcomere gene mutation (Feb. 2015)
      • Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
      • Structural and Dynamical Insight into PPARγ
      • Try our outsourcing services!
      • Identification of P-glycoprotein binders based on in house prepared diverse set of structures
      • PPARγ helix 12 exhibits an antagonist conformation
      • PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
      • Micar Innovation (Micar21) TOP 8 BioTech Award by Delta Ventures and the TOP 50 of the 2018 Startup World Cup & Summit Regional Finals!
      • Diplomatic World
      • Micar Innovation listed as a Emerging Players
      • Micar Innovation is One of 250 Companies
      • Micar Innovation (Micar21) is the winner of а prestigious award for Innovative enterprise of the year 2018
      • AI for Drug Discovery Biomarker Development
      • Discovery of the first class of dual CCR5/7 antagonists for COVID-19
      • Covid B.1.1.529
    • Scientific publications
      • Combination of Genetic Screening and Molecular Dynamics as a Useful Tool for Identification of Disease-Related Mutations: ZASP PDZ Domain G54S Mutation Case
      • Structural insight into the UNC-45–myosin complex
      • Discovery of a Novel Selective PPARγ Ligand with Partial Agonist Binding Properties by Integrated in Silico/in Vitro Work Flow
      • Molecular Basis of Inactive B-RAFWT and B-RAFV600E Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study
      • Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations
      • Structural and Dynamical Insight into PPARγ Antagonism: In silico Study of the Ligand-Receptor Interactions of non-Covalent Antagonists
      • Molecular dynamics simulation of the human estrogen receptor alpha: contribution to the pharmacophore of the agonists
      • PPARγ helix 12 exhibits an antagonist conformation
      • PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study
      • Prediction of Accurate Binding Modes using Combination of classical and accelerated Molecular dynamics and Free Energy Perturbation Calculations: An Application to Toxicity Studies
      • An Improvement of the Free Energy Perturbation (FEP+) Sampling Protocol in Case of Flexible protein Ligand Binding Sites
      • Combination of Structural based Pharmacophore and Docking Virtual Screens: An Efficient Structure-based Protocol for Lead Identification
      • Prediction of Accurate Binding Modes Using Combination of Classical and Accelerated Molecular Dynamics and Free-Energy Perturbation Calculations: An Application to Toxicity Studies
      • Discovery of New Classes of Glycine transporter 2 (GlyT2) Inhibitors and GlyT2 Selectivity Studies
      • Discovery of New AKT1 Inhibitors by Combination of In silico Structure Based Virtual Screening Approaches and Biological Evaluations
      • N501Y_mutation_manuscript
      • N501Y and K417N mutation manuscript
    • Achievements & Awards
    • Interview in the news
    • Analytics reports
    • Events

News - Scientific Publications - Awards

Company News

 

Scientific Publications

 

Awards

 

ANALYTICS REPORTS

 

Events

 

Interview in the news

 

Contact

  • Micar21 (Micar Innovation)
  • 38A, Karamfil street, 1616, Sofia, Bulgaria
  • info@micar21.com
  • www.micar21.com
  • +359 888 531345 (Time zone: +2 GMT)

For Media

If you are a journalist or a media representative and would like to write about Micar21 Drug Discovery Factory or interview our founders, please contact us at: info@Micar21.com

For Partners, Collaborations and Investors

For investor, collaboration and partner inquiries, please contact Dimitar Dimitrov: dimitar@Micar21.com

HIPPA
Cookies
Research approval

Micar21 (Micar Innovation) © 2016 - 2022 All rights reserved.